TLR Biosciences is a clinical stage start-up centered on developing topical immunotherapies for skin cancers, cervical dysplasia, and other dermal/mucosal viral diseases that are common, increasing, and serious (>$1B market). Our lead molecule is a patented TLR8 ligand that induces potent anticancer activity. Initially, we are seeking $3.5M (preclinical to IND filing) to initiate a proof-of-concept trial for the orphan indication CTCL (~18 mo).